Skip to main content

Table 4 Characteristics of local recurrent patients after curettage for GCTBa from 2008 to 2010

From: Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study

Sites Campanacci grade Pathological fracture at presentation Time to recurrence (months) Final joint preservation Embolization before curettage
Tibia II No 25 Possible No
Femur II No 60 Possible Yes
Metatarsal bone II No 60 Impossible Yes
Femur III No 6 Impossible No
Tibia III No 36 Possible Yes
Tibia II No 27 Possible No
Fibula II No 6 Possible No
Femur III No 11 Possible No
Femur II No 28 Possible No
Ulna III No 6 Possible No
Femur II No 9 Possible No
Tibia II No 21 Possible No
Femur II No 24 Impossible No
Femur III No 6 Possible No
Radius II No 6 Impossible No
Tibia III Yes 24 Possible Yes
Tibia III Yes 14 Possible No
Fibula II No 35 Possible No
Femur III Yes 21 Possible No
Lumbar spine III No 60 Not available No
Femur II No 12 Possible No
Femur III Yes 5 Possible No
Femur II No 6 Possible No
Talus II No 12 Possible No
Femur III Yes 30 Possible No
Femur III No 6 Possible No
Femur III No 22 Possible No
Femur III No 7 Possible No
Femur II No 17 Possible No
Femur I No 7 Possible No
  1. aGCTB, giant cell tumor of bone